Zárate A, Basurto L,Saucedo R, Hernandez-Valencia M

Language: Spanish
References: 17
Page: 293-296
PDF size: 28.59 Kb.

ABSTRACT

As the knowlegde in medical science development, new molecular mechanism in the diabetes had lead to new drugs and therapeutics, althought the change in life style of the patient is essential for controling the blood levels in diabetic patient glucose. Antidiabetic drugs act through different mechanisms of action, including stimulation of insulin secretion, increasing sensitivity to insulin and the insulin analogues. Other agents are inhibitors of glucose, and finally drugs which imitate intestinal hormones. It is important to emphasize that diabetes is better controlled with more than one single drug, however the corner stone of the treatment is a correct diet and exercise.

REFERENCES

1. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33(Suppl l):S11-S61.

2. Cherian B, Meka N, Katragadda S, Arora R. Therapeutic implications of diabetes in cardiovascular disease. Am J Ther 2009;16:e51-e59.

3. Hemmingsen B, Lund SS, Wetterslev J, Vaag A. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol 2009;161:1-9.

4. Lilly M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician 2009;55:363-369.

5. Kendall DM. Thiazolidinediones. Diabetes Care 2006;29:154-157

6. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457- 2471.

7. Mahler RJ, Adler ML. Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 2009;84:1165- 1171.

8. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010; 33:428-433.

9. Ahrén B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin. Diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009;23:487-498.

10. Zárate A, Hernández M, Saucedo R. Insulina para tratamiento de la diabetes. Acta Med 2008;6:91- 92.

11. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352:174-183.

12. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42.

13. Edelman S, Maier H, Wilhelm K. Pramlintide in the treatment of diabetes mellitus. BioDrugs 2008; 22:375-386.

14. Zárate A, Ochoa R, Hernández M, Basurto L. Eficacia de la acarbosa para controlar el deterioro de la tolerancia a la glucosa durante la gestación. Ginecol Obstet Mex 2000;68:42-45.

15. Rosak C, Mertes G. Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system. Curr Diabetes Rev 2009; 5:157-164.

16. Braga MF, Leiter LA. Role of renin-angiotensin system blockade in patients with diabetes mellitus. Am J Cardiol 2009;104:835-839.

17. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008;31:289-294.